|
Transient Ischemic Attack
|
0.010 |
Biomarker
|
disease |
BEFREE |
324 patients with acute ischemic stroke and TIA were further screened for PCSK9-inhibitor treatment eligibility.
|
31732461 |
2020 |
|
Hepatitis
|
0.010 |
Biomarker
|
group |
BEFREE |
Inhibited PCSK9 using CRISPR-PCSK9 adeno-associated virus in BDL mice ameliorated liver inflammation and fibrosis, with LPS decrease in serum, without any change in intestinal wall integrity.
|
31776890 |
2020 |
|
Acute lymphocytic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the present study, PCSK9 expression was measured in acute lymphoblastic leukemia (ALL) patients and was found to be significantly induced.
|
31812013 |
2020 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the present study, PCSK9 expression was measured in acute lymphoblastic leukemia (ALL) patients and was found to be significantly induced.
|
31812013 |
2020 |
|
Hematologic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
PCSK9 interferes with LDL metabolism and causes dyslipidemias in hematological malignancies particularly acute lymphoblastic leukemia.
|
31812013 |
2020 |
|
Adult Acute Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the present study, PCSK9 expression was measured in acute lymphoblastic leukemia (ALL) patients and was found to be significantly induced.
|
31812013 |
2020 |
|
Non-ST elevation (NSTEMI) myocardial infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Few studies have investigated the relationship between PCSK9 levels and the severity of coronary artery disease in patients with acute coronary syndrome; thus, we herein aimed to investigate this relationship in patients with non-ST-elevation myocardial infarction (NSTEMI) who underwent coronary angiography.
|
31206403 |
2020 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
PCSK9 interferes with LDL metabolism and causes dyslipidemias in hematological malignancies particularly acute lymphoblastic leukemia.
|
31812013 |
2020 |
|
Stroke, Lacunar
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Of 41 patients eligible for PCSK9 inhibitors, median age was 82 years (range 53-96); median vascular risk factors were 2 (range 1-5); 7 (17%) had TIA; 13 (31%) had history of preceding cerebrovascular events, 13 (31%) diabetes mellitus, 17 (42%) cardioembolic events, 9 (22%) lacunar syndrome, 11 (22%) symptomatic internal carotid artery stenosis (n = 9 were >70%), and 4 (10%) undetermined aetiology.
|
31732461 |
2020 |
|
Congenital disorder of glycosylation type 1s
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Hypolipidaemia among patients with PMM2-CDG is associated with low circulating PCSK9 levels: a case report followed by observational and experimental studies.
|
31391289 |
2020 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of the work was to examine whether abnormalities in the lipid profile that tocilizumab (TCZ), an anti-IL-6 receptor Ab, exerts in rheumatoid arthritis (RA) patients is related to changes in either proprotein convertase subtilisin/kexin-9 (PCSK9) serum concentrations or in serum cholesterol efflux capacity (CEC).
|
30695794 |
2019 |
|
Bacteremia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The plasma PCSK9 level was elevated equally in patients with Gram-positive or Gram-negative bacterial infections; particularly high levels were seen in patients with a lower respiratory tract infection and Streptococcus pneumoniae bacteraemia.
|
31166632 |
2019 |
|
Bacterial Infections
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Since there are no data on PCSK9 levels and antibiotic resistance or the severity of disease in patients with bacterial infections in intensive care units, the aim of this study was to investigate whether any such associations exist.
|
31635200 |
2019 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results revealed that PCSK9 inhibition not only exerted no harmful effects but also could moderately inhibit tumor growth, and improve lifespan and survival in mice bearing colon cancer.
|
31110520 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Among 78 patients with advanced, pre-treated NSCLC previously enrolled in a prospective study at Ospedale Policlinico San Martino in Genoa (Italy), 44 patients have been included in this sub-analysis due to the availability of serum samples for the measurement of PCSK9.
|
31327024 |
2019 |
|
Presenile dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Existing research suggests a positive association between PCSK9 expression in the brain and psychopathology, with increased levels of PCSK9 in the cerebrospinal fluid (CSF) of individuals with dementia and epigenetic modifications of PCSK9 associated with alcohol use disorder (AUD).
|
30933362 |
2019 |
|
Hyperaldosteronism
|
0.010 |
Biomarker
|
disease |
BEFREE |
The most frequent presentation of FH III is with severe hyperaldosteronism symptoms and resistance to pharmacological therapy which leads to bilateral adrenalectomy.
|
30569443 |
2019 |
|
Hyperglycemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
ANP reduced insulin-induced PCSK9, especially in the context of a medium simulating hyperglycemia.
|
30634533 |
2019 |
|
Alcoholic Liver Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease.
|
31748600 |
2019 |
|
Marijuana Abuse
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Patients with marijuana consumption had significantly higher levels of PCSK9 with a dose-response effect (p < 0.001); the association persisted after adjustment for the calculated Framingham risk score (p=0.003) and additional adjustment for clinical variables (p=0.027).
|
30827714 |
2019 |
|
Peptic Ulcer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Nominally significant associations of the PCSK9 T allele were also seen with peptic ulcer disease, depression, asthma, chronic kidney disease, and venous thromboembolism.
|
30645167 |
2019 |
|
Psoriasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings indicate that PCSK9 plays an important role in psoriasis and may be a therapeutic target.
|
30395847 |
2019 |
|
Lysosomal Storage Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Biological samples refining: Collection 1 (primary hypercholesterolemia suspected) included unrelated individuals with hyperlipidaemia and without LDLR, APOB and PCSK9 gene mutations (Set 1), and Collection 2 (LSD suspected) included individuals without definitive LSD diagnosis (Set 2).
|
31004967 |
2019 |
|
Gram-Negative Bacterial Infections
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The plasma PCSK9 level was elevated equally in patients with Gram-positive or Gram-negative bacterial infections; particularly high levels were seen in patients with a lower respiratory tract infection and Streptococcus pneumoniae bacteraemia.
|
31166632 |
2019 |
|
Alcohol abuse
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Bacteraemia patients with liver disease or a history of alcohol abuse had significantly lower levels of plasma PCSK9.
|
31166632 |
2019 |